Table 2.
Baseline Characteristics for Patients Stratified by the Level of SII and Different Glycemic Metabolism Status
| Variables | SII-H/T2DM (N=1,440) | SII-L/T2DM (N=2,516) | SII-H/Non-T2DM (N=1,687) | SII-L/Non-T2DM (N=2,959) | P value |
|---|---|---|---|---|---|
| Baseline characteristics | |||||
| Age, years | 59.68±10.29 | 59.34±9.63 | 57.28±10.60 | 57.64±10.23 | <0.001 |
| Male | 1070 (74.3) | 1867 (74.2) | 1341 (79.5) | 2333 (78.8) | <0.001 |
| BMI, kg/m2 | 26.18±3.19 | 26.31±3.12 | 25.43±3.24 | 25.68±3.16 | <0.001 |
| Hypertension | 1039 (72.2) | 1683 (66.9) | 1091 (64.7) | 1734 (58.6) | <0.001 |
| Dyslipidemia | 1004 (69.7) | 1800 (71.5) | 1042 (61.8) | 1895 (64.0) | <0.001 |
| Smoking history | 818 (56.8) | 1375 (54.7) | 979 (58.0) | 1727 (58.4) | 0.034 |
| MI history | 271 (18.8) | 526 (20.9) | 281 (16.7) | 539 (18.2) | 0.005 |
| PCI history | 357 (24.8) | 675 (26.8) | 307 (18.2) | 619 (20.9) | <0.001 |
| CABG history | 66 (4.6) | 118 (4.7) | 55 (3.3) | 98 (3.3) | 0.015 |
| Stroke history | 185 (12.8) | 306 (12.2) | 162 (9.6) | 250 (8.4) | <0.001 |
| PAD history | 129 (9.0) | 214 (8.5) | 109 (6.5) | 185 (6.3) | 0.001 |
| ACS | 939 (65.2) | 1331 (52.9) | 1096 (65.0) | 1704 (57.6) | <0.001 |
| Laboratory tests | |||||
| Platelet, *109/L | 239.45±61.17 | 189.06±44.84 | 236.83±56.75 | 190.20±43.35 | <0.001 |
| Neutrophil, *109/L | 5.57±1.90 | 3.75±1.02 | 5.13±1.44 | 3.52±0.97 | <0.001 |
| Lymphocyte, *109/L | 1.74±0.58 | 2.16±0.68 | 1.68±0.55 | 2.03±0.59 | <0.001 |
| SII | 676.04 [572.59,863.71] | 342.63 [267.90,410.63] | 662.33 [569.80,835.66] | 337.12 [269.07,411.40] | <0.001 |
| Ln SII | 6.62±0.38 | 5.77±0.32 | 6.58±0.31 | 5.78±0.31 | <0.001 |
| FBG, mmol/L | 7.94±3.04 | 7.35±2.42 | 5.21±0.59 | 5.11±0.55 | <0.001 |
| HbA1c, % | 7.41±1.29 | 7.48±1.32 | 5.88±0.33 | 5.87±0.34 | <0.001 |
| TG, mmol/L | 1.57 [1.20,2.15] | 1.59 [1.19,2.21] | 1.49 [1.13,2.02] | 1.45 [1.09,1.99] | <0.001 |
| TC, mmol/L | 4.27±1.10 | 4.19±1.10 | 4.19±1.02 | 4.18±1.05 | 0.053 |
| HDL-C, mmol/L | 1.01±0.27 | 1.02±0.27 | 1.05±0.29 | 1.06±0.28 | <0.001 |
| LDL-C, mmol/L | 2.55±0.92 | 2.48±0.91 | 2.49±0.86 | 2.50±0.91 | 0.080 |
| hsCRP, mg/L | 2.46 [1.18,6.62] | 1.49 [0.78,3.10] | 1.93 [0.90,4.75] | 1.27 [0.65,2.47] | <0.001 |
| Creatinine, μmol/L | 77.41±17.98 | 74.20±15.59 | 75.94±15.19 | 74.44±13.90 | <0.001 |
| eGFR, mL/min/1.73m2 | 99.52±23.84 | 103.83±23.03 | 102.35±21.21 | 104.10±20.49 | <0.001 |
| LVEF, % | 61.94±7.83 | 63.15±6.86 | 63.19±7.27 | 63.63±6.83 | <0.001 |
| Medications | |||||
| DAPT | 1413 (98.1) | 2469 (98.1) | 1649 (97.7) | 2876 (97.2) | 0.083 |
| β-blocker | 1324 (91.9) | 2308 (91.7) | 1503 (89.1) | 2604 (88.0) | <0.001 |
| CCB | 737 (51.2) | 1272 (50.6) | 825 (48.9) | 1407 (47.5) | 0.061 |
| Statins | 1367 (94.9) | 2400 (95.4) | 1634 (96.9) | 2857 (96.6) | 0.006 |
| Nitrate | 1402 (97.4) | 2460 (97.8) | 1660 (98.4) | 2895 (97.8) | 0.248 |
| Angiography data | |||||
| LM/three-vessel disease | 730 (50.7) | 1224 (48.6) | 659 (39.1) | 1174 (39.7) | <0.001 |
| CTO | 273 (19.0) | 410 (16.3) | 298 (17.7) | 449 (15.2) | 0.009 |
| SYNTAX score | 2.00 [1.00, 2.00] | 2.00 [1.00, 3.00] | 2.00 [1.00, 2.00] | 2.00 [1.00, 2.00] | <0.001 |
| Number of stents | 11.00 [6.00, 17.50] | 10.00 [6.00, 17.00] | 10.00 [6.00, 16.00] | 9.00 [5.00, 15.00] | <0.001 |
| Total length of stents, mm | 38.00 [23.00, 57.00] | 38.00 [24.00, 58.00] | 35.00 [23.00, 54.00] | 33.00 [23.00, 54.00] | <0.001 |
| Average diameter of stents, mm | 3.00 [2.75, 3.50] | 3.00 [2.75, 3.33] | 3.00 [2.75, 3.50] | 3.00 [2.75, 3.50] | <0.001 |
Note: Values are expressed as mean ± SD or median (IQR) for continuous variables and number (%) for categorical variables.
Abbreviations: SD, standard deviation; IQR, interquartile range; MACE, major adverse cardiovascular events; SII, systematic immune-inflammation index; T2DM, type 2 diabetes mellitus; BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; PAD, peripheral artery disease; ACS, acute coronary syndrome; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin A1c; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; DAPT, dual antiplatelet therapy; CCB, calcium channel blocker; LM, left main; SYNTAX, synergy between PCI with taxus and cardiac surgery.